Veronese, Nicola http://orcid.org/0000-0002-9328-289X
Cooper, Cyrus
Bruyère, Olivier
Al-Daghri, Nasser M.
Branco, Jaime
Cavalier, Etienne
Cheleschi, Sara
da Silva Rosa, Mario Coelho
Conaghan, Philip G.
Dennison, Elaine M.
de Wit, Maarten
Fioravanti, Antonella
Fuggle, Nicholas R.
Haugen, Ida K.
Herrero-Beaumont, Gabriel
Honvo, Germain
Laslop, Andrea
Matijevic, Radmila
Migliore, Alberto
Mobasheri, Ali
Pelletier, Jean-Pierre
Prieto Yerro, María Concepción
Radermecker, Régis Pierre
Rannou, François
Rizzoli, René
Reginster, Jean-Yves
Funding for this research was provided by:
Università degli Studi di Palermo
Article History
Accepted: 25 August 2022
First Online: 16 September 2022
Declarations
:
: Open access funding provided by Università degli Studi di Palermo within the CRUI-CARE Agreement.
: Nicola Veronese reports personal fees from IBSA, Mylan, and Fidia outside of the submitted work. Cyrus Cooper reports personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda, and UCB outside of the submitted work. Jean-Yves Reginster reports grants from IBSA-Genevrier, Mylan, CNIEL, and Radius Health (through his institution); consulting fees from IBSA-Genevrier, Mylan, CNIEL, Radius Health, and Pierre Fabre; fees for participation in review activities from IBSA-Genevrier, Mylan, CNIEL, Radius Health, and Teva; and payment for lectures from Ag-Novos, CERIN, CNIEL, Dairy Research Council (DRC), Echolight, IBSA-Genevrier, Mylan, Pfizer Consumer Health, Teva, and Theramex outside of the submitted work. Olivier Bruyère reports grants or lecture fees from Amgen, Aptissen, Biophytis, IBSA, MEDA, Mylan, Novartis, Sanofi, Servier, SMB, TRB Chemedica, UCB, and Viatris outside of the submitted work. Ali Mobasheri declares personal fees from Abbott, Abbvie, Achē Laboratórios Farmacêuticos, Galapagos, GSK Consumer Healthcare, Kolon TissueGene, Laboratoires Expansciences, Merck, Pacira Biosciences, Pfizer, Sanofi, and Servier. François Rannou reports grants or lecture fees from Pierre Fabre, Mylan, MSD, Thuasne, IBSA, Pfizer, Genévrier, Expanscience, Scarcell, Skindermic, and Peptinov. Ida K. Haugen reports grants from Pfizer and is a consultant for Novartis outside of the submitted work. Elaine M. Dennison declares grants/fees from Pfizer, Lilly, UCB, and Viatris. Philip G. Conaghan is supported in part by the National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre (the views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health), and reports consultancies or lecture fees from AbbVie, Amgen, AstraZeneca, Eli Lilly, Galapagos, GSK, Grunenthal, Pfizer, Novartis, and UCB. Nasser M. Al-Daaghri, Antonella Fioravanti, Sara Cheleschi, Jean-Pierre Pelletier, Maarten de Wit, Etienne Cavalier, Radmila Matijevic, Germain Honvo, Régis Pierre Radermecker, René Rizzoli, Jaime Branco, Andrea Laslop, María Concepción Prieto Yerro, Alberto Migliore, Gabriel Herrero-Beaumont, and Nicholas R. Fuggle declare that they have no conflicts of interest.
: Not required for this article type.
: Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
: NV, NMA, EC, SC, MCdSR, EMD, MdW, GH-B, GH, AL, J-P, and RPR wrote the draft of the manuscript. JYR, CC, OB, JB, PGC, AF, NRF, IKH, RM, AM, AM, MCPY, FR, and RR critically revised the work. All authors revised and approved the version submitted to the journal.